These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 14643073)

  • 1. Overview of the DIG trial.
    Collins JF; Egan D; Yusuf S; Garg R; Williford WO; Geller N;
    Control Clin Trials; 2003 Dec; 24(6 Suppl):269S-276S. PubMed ID: 14643073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of the data coordinating center in the DIG trial.
    Williford WO; Collins JF; Horney A; Kirk G; McSherry F; Spence E; Stinnett S; Howell CL; Garg R; Egan D; Yusuf S;
    Control Clin Trials; 2003 Dec; 24(6 Suppl):277S-288S. PubMed ID: 14643074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons learned from the DIG trial.
    Egan D; Geller N; Yusuf S; Garg R; Collins JF; Mathew J; Philbin E;
    Control Clin Trials; 2003 Dec; 24(6 Suppl):316S-326S. PubMed ID: 14643078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of regional coordinating centers in large clinical trials: the DIG trial.
    Collins JF; Martin S; Kent E; Liuni C; Garg R; Egan D;
    Control Clin Trials; 2003 Dec; 24(6 Suppl):298S-305S. PubMed ID: 14643076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the pharmacy coordinating center in the DIG trial.
    Fye CL; Gagne WH; Raisch DW; Jones MS; Sather MR; Buchanan SL; Chacon FR; Garg R; Yusuf S; Williford WO;
    Control Clin Trials; 2003 Dec; 24(6 Suppl):289S-297S. PubMed ID: 14643075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the data coordinating center in the IRB review and approval process: the DIG trial experience.
    Collins JF; Garg R; Teo KK; Williford WO; Howell CL;
    Control Clin Trials; 2003 Dec; 24(6 Suppl):306S-315S. PubMed ID: 14643077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure.
    Control Clin Trials; 1996 Feb; 17(1):77-97. PubMed ID: 8721804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digoxin use in congestive heart failure. Current status.
    Riaz K; Forker AD
    Drugs; 1998 Jun; 55(6):747-58. PubMed ID: 9617590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Digoxin's effect on mortality and hospitalization in heart failure: implications of the DIG study. Digitalis Investigation Group.
    Hobbs RE
    Cleve Clin J Med; 1997 May; 64(5):234-7. PubMed ID: 9149472
    [No Abstract]   [Full Text] [Related]  

  • 10. Association of serum digoxin concentration and outcomes in patients with heart failure.
    Rathore SS; Curtis JP; Wang Y; Bristow MR; Krumholz HM
    JAMA; 2003 Feb; 289(7):871-8. PubMed ID: 12588271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Is digoxin effective in the treatment of heart insufficiency in patients with sinus rhythm?].
    Henriksen OM; Gadsbøll N
    Ugeskr Laeger; 1999 May; 161(22):3269-74. PubMed ID: 10485204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of vital status at the end of the DIG trial.
    Collins JF; Howell CL; Horney RA;
    Control Clin Trials; 2003 Dec; 24(6):726-30. PubMed ID: 14662278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is the economic value of digoxin therapy in congestive heart failure patients? Results from the DIG trial.
    Eisenstein EL; Yusuf S; Bindal V; Bourassa MG; Horney A; Collins JF; Mark DB;
    J Card Fail; 2006 Jun; 12(5):336-42. PubMed ID: 16762794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial.
    Ahmed A; Rich MW; Fleg JL; Zile MR; Young JB; Kitzman DW; Love TE; Aronow WS; Adams KF; Gheorghiade M
    Circulation; 2006 Aug; 114(5):397-403. PubMed ID: 16864724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 200+ years of a misunderstood drug for treating chronic heart failure: digoxin, why and how should we continue using it?
    Hothi SS; Chinnappa S; Tan LB
    Int J Cardiol; 2013 Sep; 168(2):645-7. PubMed ID: 22608274
    [No Abstract]   [Full Text] [Related]  

  • 16. [Digoxin: the results of the DIG study in the XXI century].
    Helber I; Tucci PJ
    Arq Bras Cardiol; 2010 Oct; 95(4):e108-11. PubMed ID: 21180781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial.
    Abdul-Rahim AH; MacIsaac RL; Jhund PS; Petrie MC; Lees KR; McMurray JJ;
    Int J Cardiol; 2016 Apr; 209():310-6. PubMed ID: 26913372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The place of cardiac glycosides in the treatment of chronic heart failure. Part III. The DIG trial].
    Sidorenko BA; Preobrazhenskiĭ DV; Sharoshina IA; Batyraliev TA; Pershukov IV; Makhmutkhodzhaev SA
    Kardiologiia; 2005; 45(6):61-70. PubMed ID: 16007036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Digoxin remains useful in the management of chronic heart failure.
    Dec GW
    Med Clin North Am; 2003 Mar; 87(2):317-37. PubMed ID: 12693728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Digoxin Benefit Varies by Risk of Heart Failure Hospitalization: Applying the Tufts MC HF Risk Model.
    Upshaw JN; van Klaveren D; Konstam MA; Kent DM
    Am J Med; 2018 Jun; 131(6):676-683.e2. PubMed ID: 29284111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.